Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery

Ka yi Chan; Michael Baun; René de Vries; Antoon Bogaerdt; Clemens Dirven; Jan Danser; Inger Jansen-Olesen; Jes Olesen; Carlos M. Villalon Herrera; Antoinette Maassen van den Brink; Saurabh Gupta

doi:10.1177/0333102410375624

Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery

Ka yi Chan
, Michael Baun
, René de Vries
, Antoon Bogaerdt
, Clemens Dirven
, Jan Danser
, Inger Jansen-Olesen
, Jes Olesen
, Carlos M. Villalon Herrera
, Antoinette Maassen van den Brink
, Saurabh Gupta

Glostrup University Hospital
CINVESTAV (Villa Coapa)

Research output: Contribution to journal › Article › Academic › peer-review

73 Citations (Scopus)

Abstract

Objective: We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries. Methods: Concentration response curves to PACAP38, PACAP27, VIP and the VPAC(1) receptor agonist ([Lys15, Arg16, Leu27]-VIP[1-7]-GRF[8-27]) were constructed in the absence or presence of the PAC(1) receptor antagonist PACAP6-38 or the VPAC1 receptor antagonist, PG97269. mRNA expression was measured using qPCR. Results: PACAP38 was less potent than VIP in both arteries. Both peptides had lower potency and efficacy in meningeal than in coronary arteries, while mRNA expression of VPAC(1) receptor was more pronounced in meningeal arteries. PACAP6-38 reduced the E-max of PACAP27, while PG97269 right-shifted the VIP-induced relaxation curve only in the coronary arteries. Conclusion: The direct vasodilatory effect of VIP and PACAP might be less relevant than the central effect of this compound in migraine pathogenesis.

Original language	Undefined/Unknown
Pages (from-to)	181-189
Number of pages	9
Journal	Cephalalgia
Volume	31
Issue number	2
DOIs	https://doi.org/10.1177/0333102410375624
Publication status	Published - 2011

Research programs

EMC COEUR-09
EMC MM-03-44-06

Access to Document

10.1177/0333102410375624

http://hdl.handle.net/1765/31542

Cite this

@article{4edb2b4157fe43e2988fccfd6fddc692,

title = "Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery",

abstract = "Objective: We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries. Methods: Concentration response curves to PACAP38, PACAP27, VIP and the VPAC(1) receptor agonist ([Lys15, Arg16, Leu27]-VIP[1-7]-GRF[8-27]) were constructed in the absence or presence of the PAC(1) receptor antagonist PACAP6-38 or the VPAC1 receptor antagonist, PG97269. mRNA expression was measured using qPCR. Results: PACAP38 was less potent than VIP in both arteries. Both peptides had lower potency and efficacy in meningeal than in coronary arteries, while mRNA expression of VPAC(1) receptor was more pronounced in meningeal arteries. PACAP6-38 reduced the E-max of PACAP27, while PG97269 right-shifted the VIP-induced relaxation curve only in the coronary arteries. Conclusion: The direct vasodilatory effect of VIP and PACAP might be less relevant than the central effect of this compound in migraine pathogenesis.",

author = "Chan, \{Ka yi\} and Michael Baun and \{de Vries\}, Ren{\'e} and Antoon Bogaerdt and Clemens Dirven and Jan Danser and Inger Jansen-Olesen and Jes Olesen and \{Villalon Herrera\}, \{Carlos M.\} and \{Maassen van den Brink\}, Antoinette and Saurabh Gupta",

year = "2011",

doi = "10.1177/0333102410375624",

language = "Undefined/Unknown",

volume = "31",

pages = "181--189",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery

AU - Chan, Ka yi

AU - Baun, Michael

AU - de Vries, René

AU - Bogaerdt, Antoon

AU - Dirven, Clemens

AU - Danser, Jan

AU - Jansen-Olesen, Inger

AU - Olesen, Jes

AU - Villalon Herrera, Carlos M.

AU - Maassen van den Brink, Antoinette

AU - Gupta, Saurabh

PY - 2011

Y1 - 2011

N2 - Objective: We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries. Methods: Concentration response curves to PACAP38, PACAP27, VIP and the VPAC(1) receptor agonist ([Lys15, Arg16, Leu27]-VIP[1-7]-GRF[8-27]) were constructed in the absence or presence of the PAC(1) receptor antagonist PACAP6-38 or the VPAC1 receptor antagonist, PG97269. mRNA expression was measured using qPCR. Results: PACAP38 was less potent than VIP in both arteries. Both peptides had lower potency and efficacy in meningeal than in coronary arteries, while mRNA expression of VPAC(1) receptor was more pronounced in meningeal arteries. PACAP6-38 reduced the E-max of PACAP27, while PG97269 right-shifted the VIP-induced relaxation curve only in the coronary arteries. Conclusion: The direct vasodilatory effect of VIP and PACAP might be less relevant than the central effect of this compound in migraine pathogenesis.

AB - Objective: We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries. Methods: Concentration response curves to PACAP38, PACAP27, VIP and the VPAC(1) receptor agonist ([Lys15, Arg16, Leu27]-VIP[1-7]-GRF[8-27]) were constructed in the absence or presence of the PAC(1) receptor antagonist PACAP6-38 or the VPAC1 receptor antagonist, PG97269. mRNA expression was measured using qPCR. Results: PACAP38 was less potent than VIP in both arteries. Both peptides had lower potency and efficacy in meningeal than in coronary arteries, while mRNA expression of VPAC(1) receptor was more pronounced in meningeal arteries. PACAP6-38 reduced the E-max of PACAP27, while PG97269 right-shifted the VIP-induced relaxation curve only in the coronary arteries. Conclusion: The direct vasodilatory effect of VIP and PACAP might be less relevant than the central effect of this compound in migraine pathogenesis.

U2 - 10.1177/0333102410375624

DO - 10.1177/0333102410375624

M3 - Article

C2 - 20974589

SN - 0333-1024

VL - 31

SP - 181

EP - 189

JO - Cephalalgia

JF - Cephalalgia

IS - 2

ER -